Drug Type Antibody drug conjugate (ADC) |
Synonyms BL-M05D1 |
Target |
Action inhibitors |
Mechanism CLDN18.2 inhibitors(Claudin 18.2 inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Adenocarcinoma of Esophagus | Phase 1 | United States | 30 Jul 2025 | |
| Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 | United States | 30 Jul 2025 | |
| Biliary Tract Neoplasms | Phase 1 | United States | 30 Jul 2025 | |
| Metastatic Solid Tumor | Phase 1 | United States | 30 Jul 2025 | |
| stomach adenocarcinoma | Phase 1 | United States | 30 Jul 2025 | |
| Locally Advanced Malignant Solid Neoplasm | Phase 1 | China | 19 Apr 2024 |






